Tasly Pharmaceutical Stock Surges on Unexpected H1 Profit Growth

Shares of Tasly Pharmaceutical (600535.SS) surged on Wednesday after the company announced preliminary first-half 2026 profits that significantly exceeded market expectations, signaling a major improvement in operating efficiency.

The stock closed up 4.3% at 15.21 CNY following the disclosure.

Earnings Beat Drives Rally

Tasly Pharmaceutical reported in a filing that its net profit for the six months ending June 30 rose sharply, a result that caught the attention of investors. The company's performance was particularly notable given a concurrent dip in top-line revenue.

Key preliminary figures for H1 2026 include:

Ad

• Net profit attributable to shareholders: RMB 8.93 billion, an increase of approximately 15.2% year-over-year.
• Adjusted net profit (excluding non-recurring items): A surge of approximately 36% year-over-year.
• Total revenue: RMB 42.01 billion, a decrease of about 2.0% from the same period last year.

Margin Improvement Impresses Investors

The ability to deliver robust double-digit profit growth on slightly lower revenue was a key driver for the stock's rally. This dynamic points to a meaningful improvement in the company's profitability and cost management.

The source material attributes the revenue decline to tighter regulatory controls on Traditional Chinese Medicine (TCM) injections and weaker sales of cold and fever medications. For market participants, the strong profit figures suggest a positive inflection point for the company's financial health, especially as the stock had been trading near its 52-week low of 12.90 CNY earlier in the year.